

Special Issue

Progress on Seasonal and Pandemic Influenza Vaccines

Message from the Guest Editors

Vaccination is the most effective method of controlling seasonal influenza infections and preventing possible pandemic events. To date, three different classes of influenza vaccines have been licensed: inactivated, live attenuated and recombinant haemagglutinin vaccines. Most of the current influenza vaccines are still produced and/or isolated in hen's eggs; however, several novel platforms and technologies are being developed for the production of the next-generation vaccines. This special issue focuses on recent progress on seasonal and pandemic influenza vaccines. The goal is to provide an overview of different types of influenza vaccine, new technologies and platforms under development for the next-generation vaccines. This special issue invites contribution to these topics.

Dr. Claudia Trombetta

Guest Editors

Prof. Emanuele Montomoli

Department of Molecular and Developmental Medicine, Università degli Studi di Siena, Siena, Italy

Dr. Claudia Maria Trombetta

Department of Molecular and Developmental Medicine, University of Siena, Banchi di Sotto, 55, 53100 Siena, Italy

Deadline for manuscript submissions

closed (31 May 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/33017

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).